Evidence map›Paper›PMID 26297948›Full record

ArticleBiochemical and biophysical research communications2015

Identification of a PEAK1/ZEB1 signaling axis during TGFβ/fibronectin-induced EMT in breast cancer.

Megan Agajanian, Farhana Runa, Jonathan A Kelber

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical and biophysical research communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. SHEDding light on the role of Pragmin pseudo-kinases in cancer.American journal of cancer research · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Megan AgajanianDepartment of Biology, California State University Northridge, Northridge, CA 91330, USA.
Farhana RunaDepartment of Biology, California State University Northridge, Northridge, CA 91330, USA.
Jonathan A KelberDepartment of Biology, California State University Northridge, Northridge, CA 91330, USA. Electronic address: jonathan.kelber@csun.edu.
California State University, Northridge · US

Funding

SPATIOTEMPORAL MECHANISMS OF EIF5A1/2-MEDIATED METASTASIS IN TRIPLE-NEGATIVE BREAST CANCERSC1GM121182 · NIGMS · CALIFORNIA STATE UNIVERSITY NORTHRIDGE · PI KELBER, JONATHAN · 2017 to 2024
$3.2M
6 · The paper itself

Abstract

Transforming Growth Factor beta (TGFβ) is the archetypal member of the TGFβ superfamily of ligands and has pleiotropic functions during normal development, adult tissue homeostasis and pathophysiological processes such as cancer. In epithelial cancers TGFβ signaling can either suppress tumor growth or promote metastasis via the induction of a well-characterized epithelial-mesenchymal transition (EMT) program. We recently reported that PEAK1 kinase mediates signaling cross talk between TGFβ receptors and integrin/Src/MAPK pathways and functions as a critical molecular regulator of TGFβ-induced breast cancer cell proliferation, migration, EMT and metastasis. Here, we examined the breast cancer cell contexts in which TGFβ induces both EMT and PEAK1, and discovered this event to be unique to oncogene-transformed mammary epithelial cells and triple-negative breast cancer cells. Using the Cancer BioPortal database, we identified PEAK1 co-expressors across multiple malignancies that are also common to the TGFβ response gene signature (TBRS). We then used the ScanSite database to identify predicted protein-protein binding partners of PEAK1 and the PEAK1-TBRS co-expressors. Analysis of the Cytoscape interactome and Babelomics-derived gene ontologies for a novel gene set including PEAK1, CRK, ZEB1, IL11 and COL4A1 enabled us to hypothesize that PEAK1 may be regulating TGFβ-induced EMT via its interaction with or regulation of these other genes. In this regard, we have demonstrated that PEAK1 is necessary for TGFβ to induce ZEB1-mediated EMT in the context of fibronectin/ITGB3 activation. These studies and future mechanistic studies will pave the way toward identifying the context in which TGFβ blockade may significantly improve breast cancer patient outcomes.

Indexed as

Epithelial-Mesenchymal TransitionBreast NeoplasmsCell Line, TumorFemaleFibronectinsHomeodomain ProteinsHumansProtein-Tyrosine KinasesSignal TransductionTranscription FactorsTransforming Growth Factor betaZinc Finger E-box-Binding Homeobox 1FibronectinsHomeodomain ProteinsPEAK1 protein, humanProtein-Tyrosine KinasesTranscription FactorsTransforming Growth Factor betaZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Breast cancerCancer metastasisEMTPEAK1 kinaseTGFβ

Identifiers

PMID26297948
OpenAlexW1200957821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.